Figure 2.
Clinical features at LCH diagnosis of children with BRAFV600E, BRAF exon 12, or MAP2K1 mutations. (A) Pie chart showing the mutational status of the 377 patients from our cohort. (B) Dot plot showing age at diagnosis of patients with BRAFV600E, BRAF exon 12, or MAP2K1 mutations. Error bars depict medians with interquartile ranges. (C-E) Bar charts depicting the percentage of patients with BRAFV600E, BRAF exon 12, or MAP2K1 mutations having specific disease extents at LCH diagnosis. Statistical comparisons were performed for SS-bone disease in panel D and MS disease in panel E. (F-H) Bar charts depicting the percentage of patients with BRAFV600E, BRAF exon 12, or MAP2K1 mutations having specific disease sites at LCH diagnosis. Statistical tests with P < .05 are depicted. Numbers of patients are provided in Tables 1 and 2. ∗P < .05, ∗∗P < .00125. WT, wild-type.

Clinical features at LCH diagnosis of children with BRAFV600E, BRAF exon 12, or MAP2K1 mutations. (A) Pie chart showing the mutational status of the 377 patients from our cohort. (B) Dot plot showing age at diagnosis of patients with BRAFV600E, BRAF exon 12, or MAP2K1 mutations. Error bars depict medians with interquartile ranges. (C-E) Bar charts depicting the percentage of patients with BRAFV600E, BRAF exon 12, or MAP2K1 mutations having specific disease extents at LCH diagnosis. Statistical comparisons were performed for SS-bone disease in panel D and MS disease in panel E. (F-H) Bar charts depicting the percentage of patients with BRAFV600E, BRAF exon 12, or MAP2K1 mutations having specific disease sites at LCH diagnosis. Statistical tests with P < .05 are depicted. Numbers of patients are provided in Tables 1 and 2. ∗P < .05, ∗∗P < .00125. WT, wild-type.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal